医療用外骨格の世界市場：市場規模・シェア分析 (コンポーネント別・種類別・四肢別) - 産業需要の予測 (～2030年)

世界の医療用外骨格市場は、2023年に4億8,580万米ドルの規模に達し、2030年には63億3,680万米ドルにまで、44.8%のCAGRで成長します。

この産業の成長は主に、身体障害者の急増、高齢者人口の増加、整形外科手術件数の増加によるものです。

世界市場をリードする北米

北米は、2023年には55%のシェアを占めて最大の市場となり、今後数年で大きく前進します。これは、高齢者人口の急増、外骨格に対する政府支援の高まり、神経疾患の発症率の高さなどに拠ります。

アジア太平洋は、医療における資金調達の増加、最近の製品承認、移動とリハビリのサポートを必要とする患者の増加により、最も速い速度で進歩しています。

セグメント別分析

コンポーネント別ではハードウェアカテゴリーが、2023年には60%のシェアで業界をリードし、今後数年間に45.0%のCAGRで成長します。これは、外骨格が動力システム、センサー、制御システム、アクチュエーターなどの異なるハードウェアを使用して製造されるためです。

種類別では、最近の改良により動力式がシェアが大きいです。

四肢別では、2023年には下肢外骨格がリードしました。これは、足首、足、膝関節・股関節を含む下半身部位の障害の有病率の増加によるものと考えられます。

当レポートでは、世界の医療用外骨格の市場について分析し、市場の基本構造・最新情勢や主な促進・抑制要因、世界全体および地域別・主要国の市場規模の動向見通し (金額ベース、2017～2030年)、コンポーネント別・種類別・四肢別の詳細動向、現在の市場競争の状況、主要企業のプロファイルなどを調査しております。

目次

第1章 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場指標

第5章 業界の展望

• 市場力学
  • 動向
  • 促進要因
  • 抑制要因/課題
  • 促進要因/抑制要因の影響分析
• 新型コロナウイルス感染症 (COVID-19) の影響
• ポーターのファイブフォース分析

第6章 世界市場

• 概要
• 市場収益：コンポーネント別 (2017～2030年)
• 市場収益：種類別 (2017～2030年)
• 市場収益：四肢別 (2017～2030年)
• 市場収益：地域別 (2017～2030年)

第7章 北米市場

• 概要
• 市場収益：コンポーネント別 (2017～2030年)
• 市場収益：種類別 (2017～2030年)
• 市場収益：四肢別 (2017～2030年)
• 市場収益：国別 (2017～2030年)

第8章 欧州市場

第9章 アジア太平洋市場

第10章 ラテンアメリカ市場

第11章 中東・アフリカ (MEA) 市場

第12章 米国市場

• 概要
• 市場収益：コンポーネント別 (2017～2030年)
• 市場収益：種類別 (2017～2030年)
• 市場収益：四肢別 (2017～2030年)

第13章 カナダ市場

第14章 ドイツ市場

第15章 フランス市場

第16章 英国市場

第17章 イタリア市場

第18章 スペイン市場

第19章 日本市場

第20章 中国市場

第21章 インド市場

第22章 オーストラリア市場

第23章 韓国市場

第24章 ブラジル市場

第25章 メキシコ市場

第26章 サウジアラビア市場

第27章 南アフリカ市場

第28章 アラブ首長国連邦 (UAE) 市場

第29章 競合情勢

• 市場参入企業とその提供製品/サービスの一覧
• 主要企業の競合ベンチマーク
• 主要企業の製品ベンチマーク
• 最近の戦略展開状況

第30章 企業プロファイル

• Ekso Bionics Holdings Inc.
• ReWalk Robotics Ltd.
• Parker-Hannifin Corporation
• BIONIK Laboratories Corp.
• Rex Bionics Ltd.
• B-Temia Inc.
• Bioventus LLC
• Hocoma AG

第31章 付録

The medical exoskeleton market generated a value of USD 485.8 million in 2023, which will increase to USD 6,336.8 million, with a 44.8% CAGR, by 2030.

The growth of this industry is mainly because of the surging count of people with physical disabilities, the increasing elderly population, and the rising number of orthopedic surgeries.

For instance, as per the World Health Organization, an estimated 1.3 billion individuals, or 1 out of 6 people globally, experience significant disability.

Moreover, as per the United Nations, the number of people who are 65 years and above is rising at a faster rate compared to those below this age. Also, the percentage of the worldwide population aged 65 and above is likely to reach 16% in 2050 from 10% in 2022.

Furthermore, more than 300 million orthopedic operations are performed across the globe every year, 75% of which take place in developed nations.

In addition, the surging number of road accidents, strokes, and severe injuries, is also aiding the expansion of this industry. The WHO says that around 1.3 million people die annually because of road traffic crashes. Therefore, the rising acceptance of medical exoskeletons for the curing of injuries is boosting industry expansion.

North America Leading the Global Market

North America was the largest contributor to the industry in 2023, with a 55% share, and it will advance significantly in the coming years. This is because of the surging elderly population, rising government support for exoskeletons, and high incidence of neurological ailments.

For example, Human in Motion Robotics Inc. (HMR), in September 2022, declared a CAD 663,000 contract from Innovative Solutions Canada for the Department of National Defence Canada.

The contract is for the Canadian government to buy HMR's next-generation lower-extremity exoskeleton, XoMotion, which is intended to remove people's reliance on wheelchairs and enable them total mobility.

APAC is advancing at the fastest rate, owing to the increasing funding in healthcare, recent product approvals, and a growing patient pool requiring mobility and rehabilitation support.

Segmentation Analysis

The hardware category, based on component, led the industry in 2023, with a 60% share, and it will propel at a 45.0% CAGR in the coming years. This can be because exoskeletons are produced using different pieces of hardware, such as powered systems, sensors, control systems, and actuators.

The powered category, based on type, was the larger contributor to the industry, owing to the recent improvements in them. For example, Stanford University, with investment from the NIH, has developed an exoskeleton that rapidly adapts to users' movement while they walk normally.

Additionally, major players in this industry are concentrating on incorporating cutting-edge technologies like AI, to improve their product performance. AI increases the human potential, along with the efficiency of the devices.

In 2023, lower-extremity exoskeletons led the extremity category. This can be credited to the increasing prevalence of lower body parts disability, including the ankles, feet, and knee & hip joints.

Competitive Landscape

Businesses are concentrating on partnerships & acquisitions:

In November 2021, Ottobock declared the acquisition of 100% shares of suitX, a U.S.-based business spun out of the Robotics & Human Engineering Lab at the University of California, which is mostly involved in medical exoskeletons R&D.

In April 2022, Blackrock Neurotech declared that it will partner for R&D with Phantom Neuro for its patent-pending Phantom X system.

With the rising number of people with physical disabilities across the globe, the medical exoskeleton industry will continue to grow in the coming years.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by component
  • 1.4.2. Market size breakdown, by type
  • 1.4.3. Market size breakdown, by extremity
  • 1.4.4. Market size breakdown, by region
  • 1.4.5. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Component (2017-2030)
• 6.3. Market Revenue, by Type (2017-2030)
• 6.4. Market Revenue, by Extremity (2017-2030)
• 6.5. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Component (2017-2030)
• 7.3. Market Revenue, by Type (2017-2030)
• 7.4. Market Revenue, by Extremity (2017-2030)
• 7.5. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Component (2017-2030)
• 8.3. Market Revenue, by Type (2017-2030)
• 8.4. Market Revenue, by Extremity (2017-2030)
• 8.5. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Component (2017-2030)
• 9.3. Market Revenue, by Type (2017-2030)
• 9.4. Market Revenue, by Extremity (2017-2030)
• 9.5. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Component (2017-2030)
• 10.3. Market Revenue, by Type (2017-2030)
• 10.4. Market Revenue, by Extremity (2017-2030)
• 10.5. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Component (2017-2030)
• 11.3. Market Revenue, by Type (2017-2030)
• 11.4. Market Revenue, by Extremity (2017-2030)
• 11.5. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Component (2017-2030)
• 12.3. Market Revenue, by Type (2017-2030)
• 12.4. Market Revenue, by Extremity (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Component (2017-2030)
• 13.3. Market Revenue, by Type (2017-2030)
• 13.4. Market Revenue, by Extremity (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Component (2017-2030)
• 14.3. Market Revenue, by Type (2017-2030)
• 14.4. Market Revenue, by Extremity (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Component (2017-2030)
• 15.3. Market Revenue, by Type (2017-2030)
• 15.4. Market Revenue, by Extremity (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Component (2017-2030)
• 16.3. Market Revenue, by Type (2017-2030)
• 16.4. Market Revenue, by Extremity (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Component (2017-2030)
• 17.3. Market Revenue, by Type (2017-2030)
• 17.4. Market Revenue, by Extremity (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Component (2017-2030)
• 18.3. Market Revenue, by Type (2017-2030)
• 18.4. Market Revenue, by Extremity (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Component (2017-2030)
• 19.3. Market Revenue, by Type (2017-2030)
• 19.4. Market Revenue, by Extremity (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Component (2017-2030)
• 20.3. Market Revenue, by Type (2017-2030)
• 20.4. Market Revenue, by Extremity (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Component (2017-2030)
• 21.3. Market Revenue, by Type (2017-2030)
• 21.4. Market Revenue, by Extremity (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Component (2017-2030)
• 22.3. Market Revenue, by Type (2017-2030)
• 22.4. Market Revenue, by Extremity (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Component (2017-2030)
• 23.3. Market Revenue, by Type (2017-2030)
• 23.4. Market Revenue, by Extremity (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Component (2017-2030)
• 24.3. Market Revenue, by Type (2017-2030)
• 24.4. Market Revenue, by Extremity (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Component (2017-2030)
• 25.3. Market Revenue, by Type (2017-2030)
• 25.4. Market Revenue, by Extremity (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Component (2017-2030)
• 26.3. Market Revenue, by Type (2017-2030)
• 26.4. Market Revenue, by Extremity (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Component (2017-2030)
• 27.3. Market Revenue, by Type (2017-2030)
• 27.4. Market Revenue, by Extremity (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Component (2017-2030)
• 28.3. Market Revenue, by Type (2017-2030)
• 28.4. Market Revenue, by Extremity (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Ekso Bionics Holdings Inc.
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. ReWalk Robotics Ltd.
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Parker-Hannifin Corporation
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. BIONIK Laboratories Corp.
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Rex Bionics Ltd.
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. B-Temia Inc.
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Bioventus LLC
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Hocoma AG
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports